Wednesday's ETF Highlights: IHI, BITQ
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 22 2025
0mins
Source: NASDAQ.COM
ETF Performance: The Bitwise Crypto Industry Innovators ETF is down approximately 7.4% in Wednesday afternoon trading, underperforming other ETFs.
Weakest Components: Key components contributing to the ETF's decline include Hut 8, which fell by about 16.8%, and Galaxy Digital, which dropped by about 13.8%.
Market Context: The performance of the ETF reflects broader trends in the cryptocurrency market, impacting investor sentiment.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 423.630
Low
575.00
Averages
637.32
High
740.00
Current: 423.630
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TDG vs ISRG Stock Performance Comparison
- TDG Stock Movement: TDG is currently trading up approximately 0.9%, indicating a degree of market confidence that may attract investor interest in its future growth potential.
- ISRG Stock Performance: ISRG is down about 0.5%, reflecting market concerns regarding its recent performance, which could impact investor confidence and future capital inflows.
- Market Comparison Analysis: The contrasting stock movements of TDG and ISRG on the same trading day highlight differing market expectations for the future development of the two companies, potentially influencing investors' asset allocation decisions.
- Investor Sentiment: The rise in TDG may draw more investor attention, while the decline in ISRG could lead investors to reassess their portfolios, reflecting varying market perceptions of the medical device sector.
See More
Intuitive Appoints New Chief Commercial Officer to Drive Growth
- Executive Appointment: Intuitive announces the promotion of Taylor Patton, Global Senior Vice President, to Chief Commercial and Marketing Officer effective July 1, aiming to enhance the company's global market impact and customer support capabilities.
- Leadership Transition: Former CMO Henry Charlton will transition to Senior Vice President of Global Business Operations, continuing to support the company's global expansion and ensuring customers receive world-class support and service.
- Experienced Leader: With nearly two decades at Intuitive, Patton has built and scaled teams across multiple business units, and his extensive experience with the da Vinci, Ion, and Digital platforms will enhance the quality and consistency of customer support.
- Strategic Commitment: Patton is dedicated to advancing the company's efforts in providing better healthcare, helping customers achieve the Quintuple Aim by reducing treatment costs while improving patient outcomes and satisfaction.
See More
Analysis of Trump's Drug Pricing Policy Impact
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to cap U.S. drug prices to match those of other developed nations, potentially impacting government programs like Medicare and leading to decreased sales and profits for drugmakers.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue for 2023, reflecting a 7% year-over-year increase and demonstrating resilience in its diversified healthcare portfolio.
- New Product Development: Johnson & Johnson is seeking U.S. approval for its robotic-assisted surgery device, the Ottava system, which, despite competition, could benefit from the growing demand for minimally invasive procedures due to an aging population.
- Acquisition and Growth: Roche's acquisition of SAGA Diagnostics for up to $595 million aims to strengthen its position in the molecular residual disease testing market, which is one of the fastest-growing areas in diagnostics, potentially offsetting pressures from drug pricing policies.
See More
Trump's Drug Price Policy Could Impact Pharma Profits
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to limit the prices the U.S. government pays for certain drugs, potentially triggering a domino effect on pharmaceutical companies' sales and profits in the world's largest pharmaceutical market.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue this year, reflecting a 7% year-over-year increase and showcasing its resilience and adaptability in the diversified healthcare sector.
- Acquisition and Innovation: Roche's acquisition of SAGA Diagnostics, costing up to $595 million, aims to strengthen its position in the rapidly growing molecular residual disease testing market for cancer, which is expected to drive growth in its diagnostics business.
- Diversification Advantage: The diversified portfolios of Johnson & Johnson and Roche enable them to maintain competitiveness under Trump's drug pricing policies, particularly through ongoing innovation and investment in medical devices and diagnostics.
See More
Intuitive Surgical and Microsoft: Long-Term Investment Opportunities
- Financial Challenges for ISRG: Despite facing steep tariffs, Intuitive Surgical reported significant revenue and procedure volume growth in Q1, solidifying its market leadership in robotic-assisted surgery and indicating strong long-term growth potential.
- New Product Momentum: The latest da Vinci model accounted for 54% of the company's system placements in Q1, and its strong market adoption not only enhances technological advantages but also provides valuable feedback for future product improvements.
- Microsoft's AI Revenue Surge: Microsoft plans to invest $190 billion in AI-related capital expenditures by 2026, with its AI business already achieving an annual revenue run rate of $37 billion, reflecting a 123% year-over-year growth and showcasing the company's robust performance in the AI revolution.
- Cloud Computing Leadership: Microsoft's cloud backlog surged 99% year-over-year to $627 billion in the latest quarter, and combined with its AAA credit rating and a 153% dividend increase over the past decade, this further solidifies its appeal as a long-term investment.
See More
Market Outlook for Intuitive Surgical and Microsoft
- Solid Financial Performance: Despite facing steep tariffs, Intuitive Surgical achieved significant revenue and procedure volume growth in Q1, further solidifying its market leadership in robotic-assisted surgery, demonstrating the company's strong competitive position in the medical device sector.
- Sustained Technological Edge: The latest da Vinci 5 model accounted for nearly 54% of the company's installed systems in Q1, and this strong market acceptance not only enhances the company's technological advantage but also provides valuable feedback for future product improvements.
- AI-Driven Growth Potential: Microsoft plans to invest $190 billion by 2026 to support its AI-related strategies; despite concerns about its services being replaced by AI, the company has already achieved an annual revenue run rate of $37 billion in its AI business, reflecting a 123% year-over-year growth and showcasing its adaptability in technological transformation.
- Cloud Market Leadership: Microsoft's cloud backlog surged 99% year-over-year to $627 billion in the most recent quarter, and combined with its AAA credit rating and a 153% dividend increase over the past decade, this further underscores its attractiveness as a long-term investment.
See More
TDG vs ISRG Stock Performance Comparison
- TDG Stock Movement: TDG is currently trading up approximately 0.9%, indicating a degree of market confidence that may attract investor interest in its future growth potential.
- ISRG Stock Performance: ISRG is down about 0.5%, reflecting market concerns regarding its recent performance, which could impact investor confidence and future capital inflows.
- Market Comparison Analysis: The contrasting stock movements of TDG and ISRG on the same trading day highlight differing market expectations for the future development of the two companies, potentially influencing investors' asset allocation decisions.
- Investor Sentiment: The rise in TDG may draw more investor attention, while the decline in ISRG could lead investors to reassess their portfolios, reflecting varying market perceptions of the medical device sector.
See More
Intuitive Appoints New Chief Commercial Officer to Drive Growth
- Executive Appointment: Intuitive announces the promotion of Taylor Patton, Global Senior Vice President, to Chief Commercial and Marketing Officer effective July 1, aiming to enhance the company's global market impact and customer support capabilities.
- Leadership Transition: Former CMO Henry Charlton will transition to Senior Vice President of Global Business Operations, continuing to support the company's global expansion and ensuring customers receive world-class support and service.
- Experienced Leader: With nearly two decades at Intuitive, Patton has built and scaled teams across multiple business units, and his extensive experience with the da Vinci, Ion, and Digital platforms will enhance the quality and consistency of customer support.
- Strategic Commitment: Patton is dedicated to advancing the company's efforts in providing better healthcare, helping customers achieve the Quintuple Aim by reducing treatment costs while improving patient outcomes and satisfaction.
See More
Analysis of Trump's Drug Pricing Policy Impact
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to cap U.S. drug prices to match those of other developed nations, potentially impacting government programs like Medicare and leading to decreased sales and profits for drugmakers.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue for 2023, reflecting a 7% year-over-year increase and demonstrating resilience in its diversified healthcare portfolio.
- New Product Development: Johnson & Johnson is seeking U.S. approval for its robotic-assisted surgery device, the Ottava system, which, despite competition, could benefit from the growing demand for minimally invasive procedures due to an aging population.
- Acquisition and Growth: Roche's acquisition of SAGA Diagnostics for up to $595 million aims to strengthen its position in the molecular residual disease testing market, which is one of the fastest-growing areas in diagnostics, potentially offsetting pressures from drug pricing policies.
See More
Trump's Drug Price Policy Could Impact Pharma Profits
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to limit the prices the U.S. government pays for certain drugs, potentially triggering a domino effect on pharmaceutical companies' sales and profits in the world's largest pharmaceutical market.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue this year, reflecting a 7% year-over-year increase and showcasing its resilience and adaptability in the diversified healthcare sector.
- Acquisition and Innovation: Roche's acquisition of SAGA Diagnostics, costing up to $595 million, aims to strengthen its position in the rapidly growing molecular residual disease testing market for cancer, which is expected to drive growth in its diagnostics business.
- Diversification Advantage: The diversified portfolios of Johnson & Johnson and Roche enable them to maintain competitiveness under Trump's drug pricing policies, particularly through ongoing innovation and investment in medical devices and diagnostics.
See More
Intuitive Surgical and Microsoft: Long-Term Investment Opportunities
- Financial Challenges for ISRG: Despite facing steep tariffs, Intuitive Surgical reported significant revenue and procedure volume growth in Q1, solidifying its market leadership in robotic-assisted surgery and indicating strong long-term growth potential.
- New Product Momentum: The latest da Vinci model accounted for 54% of the company's system placements in Q1, and its strong market adoption not only enhances technological advantages but also provides valuable feedback for future product improvements.
- Microsoft's AI Revenue Surge: Microsoft plans to invest $190 billion in AI-related capital expenditures by 2026, with its AI business already achieving an annual revenue run rate of $37 billion, reflecting a 123% year-over-year growth and showcasing the company's robust performance in the AI revolution.
- Cloud Computing Leadership: Microsoft's cloud backlog surged 99% year-over-year to $627 billion in the latest quarter, and combined with its AAA credit rating and a 153% dividend increase over the past decade, this further solidifies its appeal as a long-term investment.
See More
Market Outlook for Intuitive Surgical and Microsoft
- Solid Financial Performance: Despite facing steep tariffs, Intuitive Surgical achieved significant revenue and procedure volume growth in Q1, further solidifying its market leadership in robotic-assisted surgery, demonstrating the company's strong competitive position in the medical device sector.
- Sustained Technological Edge: The latest da Vinci 5 model accounted for nearly 54% of the company's installed systems in Q1, and this strong market acceptance not only enhances the company's technological advantage but also provides valuable feedback for future product improvements.
- AI-Driven Growth Potential: Microsoft plans to invest $190 billion by 2026 to support its AI-related strategies; despite concerns about its services being replaced by AI, the company has already achieved an annual revenue run rate of $37 billion in its AI business, reflecting a 123% year-over-year growth and showcasing its adaptability in technological transformation.
- Cloud Market Leadership: Microsoft's cloud backlog surged 99% year-over-year to $627 billion in the most recent quarter, and combined with its AAA credit rating and a 153% dividend increase over the past decade, this further underscores its attractiveness as a long-term investment.
See More
